[go: up one dir, main page]

EP0859620A1 - Nitrogen monoxide composition for use as a drug - Google Patents

Nitrogen monoxide composition for use as a drug

Info

Publication number
EP0859620A1
EP0859620A1 EP96934928A EP96934928A EP0859620A1 EP 0859620 A1 EP0859620 A1 EP 0859620A1 EP 96934928 A EP96934928 A EP 96934928A EP 96934928 A EP96934928 A EP 96934928A EP 0859620 A1 EP0859620 A1 EP 0859620A1
Authority
EP
European Patent Office
Prior art keywords
nitrogen monoxide
abdominal
gaseous
concentration
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96934928A
Other languages
German (de)
French (fr)
Inventor
Robert Briend
Marie-Hélène Renaudin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Air Liquide SA
Publication of EP0859620A1 publication Critical patent/EP0859620A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the use of a stable gaseous composition based on nitrogen monoxide (NO) and carbon dioxide
  • Nitric oxide is produced naturally in mammals by an enzyme, NO-synthase, which is expressed constitutively in endothelial cells, in platelets, and in the central and peripheral nervous systems. Another form of calcium-independent NO-synthase can be induced by different stimuli (notably liposaccharides) in many cells such as macrophages, lymphocytes, myocardial cells, endothelial cells and smooth muscle cells. Nitric oxide is an important biological messenger in mammals and this molecule plays a decisive role in the local control of hemodynamics.
  • Nitric oxide also controls post-capillary venous permeability.
  • Nitric oxide also participates in hormonal regulation mechanisms, at the kidney level by inhibiting the release of renin, at the cardiovascular level, by antagonizing the release of natriuretic factor (ANF).
  • NAF natriuretic factor
  • platelet activation is under the permanent control of endothelial nitric oxide, and to a lesser extent under that of platelet NO synthase.
  • the platelets release nucleotides (ATP, ADP), serotonin, PAF, thromboxane A2 and vasopressin; they can also initiate the coagulation cascade by releasing thrombin.
  • ATP nucleotides
  • ADP serotonin
  • PAF thromboxane A2
  • vasopressin vasopressin
  • endothelial cells release NO and prostacyclin which act synergistically to prevent and counter the platelet aggregation process.
  • vasodilators have been developed to date: these substances known under the designation of nitrovasodilators produce NO in vivo and thus compensate for a defect in endogenous NO. There may be mentioned, for example, molsidomine or sodium nitroprusside, which make it possible to prevent the phenomena of adhesion and platelet aggregation.
  • L-arginine In order to compensate for an insufficient production of NO, the administration of L-arginine or of analogues of L-arginine has also been proposed, L-arginine intervening directly in the biosynthesis of nitrogen monoxide, in as a substrate for NO-synthase.
  • Surgical procedures by laparoscopy are more and more practiced because they allow, compared to the conventional techniques of open laparotomies, to reduce not only the duration of hospitalization, but also the healing time and thereby postoperative pain.
  • the laparoscopy technique is usually accompanied by insufflation in the abdomen (intra or extra-peritoneal insufflation) of a gas, such as C0 2 , which insufflation causes an increase in the pressure exerted at l inside the abdomen.
  • a gas such as C0 2
  • the purpose of the present invention is therefore to alleviate the problems set out above.
  • the invention then relates to the use of a gaseous composition containing nitrogen monoxide (NO) and carbon dioxide (C0 2 ) for the manufacture of a gaseous medicament intended for the treatment or prophylaxis by intra-abdominal hypoperfusions of the abdominal organs.
  • intra-abdominal route is meant intra or extra-peritoneal route.
  • the drug NO / C0 2 mixture of the invention is particularly suitable for administration by intra-abdominal insufflation during a laparoscopic or laparoscopic intervention; the peritoneum designating the serous membrane lining the cavity of the abdomen.
  • the gaseous medicament of the invention preferably consists of the only mixture of carbon dioxide and nitrogen monoxide; however, the addition of at least one gas chosen from the group formed by xenon, krypton, nitrous oxide and their mixtures, to said mixture of C0 2 and NO is conceivable.
  • the concentration of NO in the NO + C0 2 gas mixture is an effective concentration, preferably between 1 and 100 ppm.
  • a concentration of less than 1 ppm is not desirable and a concentration of more than 100 ppm results in a progressive disappearance of the therapeutic effect.
  • the reasons for the low activity observed at such concentrations are still unknown, but could be linked to local toxicity or possibly to saturation of the nitrogen monoxide receptors.
  • the concentration of NO in the drug mixture is between 15 and 30 ppm.
  • the stability of the gaseous medicament of the invention allows it to be stored under pressure in conventional containers of the type steel bottles or light alloy based on aluminum. In order to avoid any risk of contamination, we will advantageously opt for light alloy based on aluminum.
  • the preferred storage conditions ensuring stability greater than 2 years are a temperature between 15 and 30 ° C, preferably 20 and 25 ° C, and a pressure between 20 and 30 bars.
  • compositions of the invention can be administered by intra-abdominal insufflation, and more particularly by intraperitoneal insufflation. To do this, we will proceed in a manner known per se. After abdominal incision, the NO / C0 2 composition is injected into the abdominal cavity by means of a needle connected to an insufflator such as a Medicam 900 MP type video insufflator. During the entire duration of the intervention, an internal pressure of 10 to 20 mm of Hg is maintained in the abdominal cavity. Note that the blowing of a mixture of C0 2 and nitrogen monoxide is neither described nor suggested in the literature.
  • the vasodilating and anti-aggregating activity of NO platelets makes the composition of the invention particularly suitable for the treatment of side effects linked to a reduction in the vascularization of the intra-abdominal organs during laparoscopic procedures.
  • the amount of drug composition to be administered depends, for its part, on the age of the patient, the severity of the condition from which he suffers and the NO concentration of the gaseous composition injected. Examples 1 to 3 which follow illustrate the stability of the compositions of the invention, as well as their therapeutic utility, with reference to Figures 1 and 2 appended.
  • the value of the NO concentration is measured by a chemiluminescence analyzer in the range from 0 to 100 ppm, calibrated before each measurement using a standard NO / N 2 mixture at 90 ppm.
  • the chemiluminescence analyzer used is the TOPAZE 2020 manufactured by COSMA.
  • This example aims to demonstrate the effectiveness of the composition NO / C0 2 of the invention, administered by intraperitoneal insufflation, in the fight against hypoperfusion of the abdominal organs, and in particular of the kidneys.
  • Doppler ⁇ sensors are implanted on the renal artery so as to measure the diameter of the arterial vessel and the speed of the blood in order to assess the average renal blood flow.
  • a urinary catheter is installed in the urethra in order to measure the urine flow.
  • the 8 pigs are divided into 2 groups of 4 pigs each. These 2 groups of 4 pigs undergo intraperitoneal insufflation, for 2 hours and at a pressure of 15 mm Hg, of:
  • a drop in blood flow and diuresis is observed in the 2 groups of pigs, from the start of insufflation. However, the drop is less for group 2 (NO / C0 2 blown). In fact, after insufflation, the blood flow and diuresis values obtained for group 2 are 20% to 30% higher than those obtained for group 1.
  • the gaseous composition of N0 / C0 2 of the invention does indeed make it possible to combat hypoperfusions of the abdominal organs, when it is administered intra-abdominally, that is to say extra or intra-peritoneal, in allowing in particular an increase in blood flow to the abdominal organs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PCT No. PCT/FR96/01624 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Oct. 17, 1996 PCT Pub. No. WO97/15312 PCT Pub. Date May 1, 1997The invention relates to a method for the treatment or prevention of hypoperfusions of abdominal organs comprising administering a gaseous medication containing nitrogen monoxide and carbon dioxide to the patient. The gaseous medication is administered by the intra-abdominal route.

Description

COMPOSITION A BASE DE MONOXYDE D'AZOTE EN TANT QUE NITROGEN MONOXIDE COMPOSITION AS
MEDICAMENTDRUG
La présente invention se rapporte à l'utilisation d'une composition gazeuse stable à base de monoxyde d'azote (NO) et de dioxyde de carboneThe present invention relates to the use of a stable gaseous composition based on nitrogen monoxide (NO) and carbon dioxide
(CO2) pour la fabrication d'un médicament gazeux destiné au traitement ou à la prophylaxie par voie intra-abdominale des hypoperfusions des organes abdominaux, en particulier lors d'une intervention en coelioscopie ou en coeliochirurgie.(CO 2 ) for the manufacture of a gaseous medicament intended for the treatment or prophylaxis by intra-abdominal route of hypoperfusions of the abdominal organs, in particular during a laparoscopic or laparoscopic intervention.
Le monoxyde d'azote est produit naturellement chez le mammifère par une enzyme, la NO-synthase, laquelle est exprimée de façon constitutive dans les cellules endothéliales, dans les plaquettes et dans le système nerveux central et périphérique. Une autre forme de NO-synthase calcium-indépendante, peut être induite par différents stimuli (notamment des liposaccharides) dans de nombreuses cellules telles que les macrophages, les lymphocytes, les cellules myocardiques, les cellules endothéliales et les cellules musculaires lisses. Le monoxyde d'azote est un messager biologique important chez les mammifères et cette molécule joue un rôle déterminant dans le contrôle local de 1'hémodynamique.Nitric oxide is produced naturally in mammals by an enzyme, NO-synthase, which is expressed constitutively in endothelial cells, in platelets, and in the central and peripheral nervous systems. Another form of calcium-independent NO-synthase can be induced by different stimuli (notably liposaccharides) in many cells such as macrophages, lymphocytes, myocardial cells, endothelial cells and smooth muscle cells. Nitric oxide is an important biological messenger in mammals and this molecule plays a decisive role in the local control of hemodynamics.
On a pu mettre en évidence la libération de NO par les cellules endothéliales en cas de variations du débit sanguin. Le monoxyde d'azote apparaît notamment comme une composante majeure de l'adaptation physiologique du diamètre vasculaire à la perfusion sanguine : ainsi au niveau coronaire, l'hypérémie réactive est atténuée de façon notoire. Inversement, une augmentation chronique du débit sanguin produite par une fistule artérioveineuse augmente les relaxations dépendantes de l'endothélium. La capacité du monoxyde d'azote produit au niveau de la paroi vasculaire et dans les tissus avoisinants à réguler de façon précise le tonus vasculaire par adaptation du débit sanguin est remarquable. De même, on a émis l'hypothèse que le NO libéré lors de l'activité neuronale pourrait réguler le tonus de la microcirculation cérébrale, couplant ainsi l'activité et le débit sanguin cérébral. On rappellera également le rôle de NO dans la régulation de la prolifération du muscle lisse vasculaire laquelle est un facteur déterminant de la compliance vasculaire.It was possible to demonstrate the release of NO by the endothelial cells in the event of variations in blood flow. Nitrogen monoxide appears in particular as a major component of the physiological adaptation of the vascular diameter to blood perfusion: thus at the coronary level, reactive hyperemia is markedly attenuated. Conversely, a chronic increase in blood flow produced by an arteriovenous fistula increases dependent relaxations of the endothelium. The capacity of nitric oxide produced at the level of the vascular wall and in the tissues neighboring to precisely regulate the vascular tone by adaptation of blood flow is remarkable. Likewise, it has been hypothesized that the NO released during neuronal activity could regulate the tone of the cerebral microcirculation, thus coupling activity and cerebral blood flow. The role of NO in regulating the proliferation of vascular smooth muscle, which is a determining factor in vascular compliance, will also be recalled.
Le monoxyde d'azote contrôle par ailleurs la perméabilité veinulaire post-capillaire.Nitric oxide also controls post-capillary venous permeability.
Le monoxyde d'azote participe aussi à des mécanismes de régulation hormonale, au niveau du rein en inhibant la libération de rénine, au niveau cardio-vasculaire, en antagonisant la libération du facteur natriurétique (ANF) .Nitric oxide also participates in hormonal regulation mechanisms, at the kidney level by inhibiting the release of renin, at the cardiovascular level, by antagonizing the release of natriuretic factor (ANF).
Enfin, in vivo, l'activation plaquettaire est sous le contrôle permanent du monoxyde d'azote endothélial, et dans un moindre degré sous celui de la propre NO synthase plaquettaire. Lors de l'agrégation, les plaquettes libèrent des nucléotides (ATP, ADP) , de la sérotonine, du PAF, du thromboxane A2 et de la vasopressine; elles peuvent aussi initier la cascade de la coagulation en libérant de la thrombine. En réponse à l'ATP, l'ADP, la sérotonine, le PAF et la thrombine, les cellules endothéliales libèrent du NO et de la prostacycline qui agissent en synergie pour prévenir et contrer le processus d'agrégation plaquettaire.Finally, in vivo, platelet activation is under the permanent control of endothelial nitric oxide, and to a lesser extent under that of platelet NO synthase. During aggregation, the platelets release nucleotides (ATP, ADP), serotonin, PAF, thromboxane A2 and vasopressin; they can also initiate the coagulation cascade by releasing thrombin. In response to ATP, ADP, serotonin, PAF and thrombin, endothelial cells release NO and prostacyclin which act synergistically to prevent and counter the platelet aggregation process.
La diminution anormale du taux de monoxyde d'azote observée dans le cas de nombreuses pathologies semble confirmer l'importance du rôle joué par celui-ci dans l'organisme. Une telle diminution est caractéristique de l'hypertension, de 1 'hypercholestérolémie, de l'athérosclérose et du diabète.The abnormal decrease in the level of nitric oxide observed in the case of many pathologies seems to confirm the importance of the role played by it in the body. Such a decrease is characteristic of hypertension, hypercholesterolemia, atherosclerosis and diabetes.
De même, une réduction très précoce de la libération basale de NO serait à l'origine des troubles liés à la reperfusion de territoires ischémies, tels que la thrombose coronaire et le vasospasme.Likewise, a very early reduction in the basal release of NO would be at the origin of disorders linked to the reperfusion of ischemic areas, such as coronary thrombosis and vasospasm.
Sur la base de ces diverses constatations, divers agents vasodilatateurs ont été mis au point à ce jour : ces substances connues sous la désignation de nitrovasodilatateurs produisent du NO in vivo et suppléent ainsi à un défaut de NO endogène. On peut citer, par exemple, la molsidomine ou le nitroprussiate de sodium, lesquels permettent de prévenir les phénomènes d'adhésion et d'agrégation plaquettaire.On the basis of these various findings, various vasodilators have been developed to date: these substances known under the designation of nitrovasodilators produce NO in vivo and thus compensate for a defect in endogenous NO. There may be mentioned, for example, molsidomine or sodium nitroprusside, which make it possible to prevent the phenomena of adhesion and platelet aggregation.
De façon à pallier une production insuffisante de NO, on a, de même, proposé l'administration de L- arginine ou d'analogues de la L-arginine, la L- arginine intervenant directement dans la biosynthèse du monoxyde d'azote, en tant que substrat de la NO- synthase.In order to compensate for an insufficient production of NO, the administration of L-arginine or of analogues of L-arginine has also been proposed, L-arginine intervening directly in the biosynthesis of nitrogen monoxide, in as a substrate for NO-synthase.
Au vu de la contribution significative du monoxyde d'azote au maintien d'une basse pression au niveau de la circulation pulmonaire et de l'importance de l'effet vasodilatateur local résultant, on a, par ailleurs, suggéré l'administration directe de NO par voie inhalée dans le traitement de l'hypertension artérielle pulmonaire aiguë. Les nombreuses recherches réalisées en ce sens ont démontré l'efficacité thérapeutique d'un mélange gazeux de monoxyde d'azote et d'azote inhalé à des doses comprises entre 1 et 20 ppm de NO sur des patients souffrant de détresse respiratoire aiguë : une réduction de l'hypertension artérielle pulmonaire éventuellement accompagnée d'une amélioration des rapports ventilation-perfusion par baisse du shunt intrapulmonaire sont en effet observées.In view of the significant contribution of nitric oxide to the maintenance of a low pressure in the pulmonary circulation and of the importance of the local vasodilator effect resulting, it was further suggested that direct administration of NO inhaled for the treatment of acute pulmonary hypertension. Numerous researches carried out in this direction have demonstrated the therapeutic efficacy of a gaseous mixture of nitric oxide and inhaled nitrogen at doses between 1 and 20 ppm of NO on patients suffering from acute respiratory distress: a reduction pulmonary arterial hypertension possibly accompanied by an improvement in ventilation-perfusion ratios by reduction of the shunt intrapulmonary are indeed observed.
Les interventions chirurgicales par coelioscopie sont de plus en plus pratiquées car elles permettent, par rapport aux techniques conventionnelles de laparotomies ouvertes, de réduire non seulement la durée d'hospitalisation, mais aussi le temps de cicatrisation et par là même les douleurs post¬ opératoires.Surgical procedures by laparoscopy are more and more practiced because they allow, compared to the conventional techniques of open laparotomies, to reduce not only the duration of hospitalization, but also the healing time and thereby postoperative pain.
Cependant, bien que cette technique de coelioscopie présente de nombreux avantages, elle présente également un inconvénient majeur.However, although this laparoscopy technique has many advantages, it also has a major drawback.
En effet, la technique de coelioscopie s'accompagne habituellement d'une insufflation dans l'abdomen (insufflation intra ou extra-péritonéale) d'un gaz, tel le C02, laquelle insufflation provoque une augmentation de la pression s'exerçant à l'intérieur de l'abdomen.Indeed, the laparoscopy technique is usually accompanied by insufflation in the abdomen (intra or extra-peritoneal insufflation) of a gas, such as C0 2 , which insufflation causes an increase in the pressure exerted at l inside the abdomen.
De cette augmentation de pression intra- abdominale, il résulte une diminution, néfaste pour le patient, des débits sanguins des organes abdominaux, en particulier des reins et de l'intestin, et une affection des fonctions associées à ces organes abdominaux, tels que la diurèse et le transit intestinal. Ces perturbations sont dues essentiellement à un phénomène d'hypoperfusion de ces organes, lié à l'augmentation de pression due à l'insufflation, et sont d'autant plus néfastes pour le patient que la durée d'intervention, c'est-à-dire de l'opération chirurgicale, est importante.From this increase in intra-abdominal pressure, there results a decrease, harmful for the patient, of the blood flow of the abdominal organs, in particular of the kidneys and the intestine, and an affection of the functions associated with these abdominal organs, such as diuresis and intestinal transit. These disturbances are mainly due to a phenomenon of hypoperfusion of these organs, linked to the increase in pressure due to insufflation, and are all the more harmful for the patient as the duration of intervention, i.e. -tell about the surgical operation, is important.
Les but de la présente invention eεt donc de pallier les problèmes ci-dessus exposés.The purpose of the present invention is therefore to alleviate the problems set out above.
L'invention se rapporte alors à l'utilisation d'une composition gazeuse contenant du monoxyde d'azote (NO) et du dioxyde de carbone (C02) pour la fabrication d'un médicament gazeux destiné au traitement ou à la prophylaxie par voie intra- abdominale des hypoperfusions des organes abdominaux. Par voie intra-abdominale, on entend voie intra ou extra-péritonéale. Le mélange médicamenteux NO/C02 de l'invention est particulièrement adapté à une administration par insufflation intra-abdominale lors d'une intervention en coelioscopie ou en coeliochirurgie; le péritoine désignant la membrane séreuse tapissant la cavité de l'abdomen.The invention then relates to the use of a gaseous composition containing nitrogen monoxide (NO) and carbon dioxide (C0 2 ) for the manufacture of a gaseous medicament intended for the treatment or prophylaxis by intra-abdominal hypoperfusions of the abdominal organs. By intra-abdominal route is meant intra or extra-peritoneal route. The drug NO / C0 2 mixture of the invention is particularly suitable for administration by intra-abdominal insufflation during a laparoscopic or laparoscopic intervention; the peritoneum designating the serous membrane lining the cavity of the abdomen.
Le médicament gazeux de l'invention est, de préférence, constitué du seul mélange de gaz carbonique et de monoxyde d'azote; toutefois, l'addition d'au moins un gaz choisi dans le groupe formé par le xénon, le krypton, le protoxyde d'azote et leurs mélanges, audit mélange de C02 et de NO est envisageable.The gaseous medicament of the invention preferably consists of the only mixture of carbon dioxide and nitrogen monoxide; however, the addition of at least one gas chosen from the group formed by xenon, krypton, nitrous oxide and their mixtures, to said mixture of C0 2 and NO is conceivable.
La concentration de NO dans le mélange gazeux NO + C02 est une concentration efficace, de préférence comprise entre 1 et 100 ppm. Une concentration inférieure à 1 ppm n'est pas souhaitable et une concentration supérieure à 100 ppm entraîne une disparition progressive de l'effet thérapeutique. Les raisons du peu d'activité observée à de telles concentrations sont encore inconnues, mais pourraient être liées à une toxicité locale ou éventuellement à la saturation des récepteurs du monoxyde d'azote.The concentration of NO in the NO + C0 2 gas mixture is an effective concentration, preferably between 1 and 100 ppm. A concentration of less than 1 ppm is not desirable and a concentration of more than 100 ppm results in a progressive disappearance of the therapeutic effect. The reasons for the low activity observed at such concentrations are still unknown, but could be linked to local toxicity or possibly to saturation of the nitrogen monoxide receptors.
Selon un mode de réalisation préféré, la concentration de NO dans le mélange médicamenteux est comprise entre 15 et 30 ppm.According to a preferred embodiment, the concentration of NO in the drug mixture is between 15 and 30 ppm.
La stabilité du médicament gazeux de l'invention permet son stockage sous pression dans des conditionnements classiques du type bouteilles en acier ou alliage léger à base d'aluminium. De façon à éviter tout risque de contamination, on optera avantageusement pour des bouteilles en alliage léger à base d'aluminium. Les conditions de stockage préférées assurant une stabilité supérieure à 2 ans sont une température comprise entre 15 et 30°C, de préférence 20 et 25°C, et une pression comprise entre 20 et 30 bars.The stability of the gaseous medicament of the invention allows it to be stored under pressure in conventional containers of the type steel bottles or light alloy based on aluminum. In order to avoid any risk of contamination, we will advantageously opt for light alloy based on aluminum. The preferred storage conditions ensuring stability greater than 2 years are a temperature between 15 and 30 ° C, preferably 20 and 25 ° C, and a pressure between 20 and 30 bars.
Les compositions de l'invention sont administrables par insufflation intra-abdominale, et plus particulièrement par insufflation intra- péritonéale. Pour ce faire, on procédera d'une façon connue en soi. Après incision abdominale, la composition NO/C02 est insufflée dans la cavité abdominale au moyen d'une aiguille reliée à un insufflateur tel qu'un insufflateur de type MP vidéo Medicam 900. Pendant tout la durée de l'intervention une pression interne de 10 à 20 mm de Hg est maintenue dans le cavité abdominale. On notera que l'insufflation d'un mélange de C02 et de monoxyde d'azote n'est ni décrite ni suggérée dans la littérature. L'activité vasodilatatrice et antiagrégante plaquettaire du NO rend la composition de l'invention particulièrement adaptée au traitement des effets secondaires liés à une diminution de la vascularisation des organes intra-abdominaux pendant les interventions sous coelioscopie. La quantité de composition médicamenteuse devant être administrée dépend, quant à elle, de l'âge du patient, de la gravité de l'affection dont il souffre et de la concentration en NO de la composition gazeuse injectée. Les exemples 1 à 3 qui suivent illustrent la stabilité des compositions de l'invention, ainsi que leur utilité thérapeutique, en référence aux Figures 1 et 2 annexées. EXEMPLE 1The compositions of the invention can be administered by intra-abdominal insufflation, and more particularly by intraperitoneal insufflation. To do this, we will proceed in a manner known per se. After abdominal incision, the NO / C0 2 composition is injected into the abdominal cavity by means of a needle connected to an insufflator such as a Medicam 900 MP type video insufflator. During the entire duration of the intervention, an internal pressure of 10 to 20 mm of Hg is maintained in the abdominal cavity. Note that the blowing of a mixture of C0 2 and nitrogen monoxide is neither described nor suggested in the literature. The vasodilating and anti-aggregating activity of NO platelets makes the composition of the invention particularly suitable for the treatment of side effects linked to a reduction in the vascularization of the intra-abdominal organs during laparoscopic procedures. The amount of drug composition to be administered depends, for its part, on the age of the patient, the severity of the condition from which he suffers and the NO concentration of the gaseous composition injected. Examples 1 to 3 which follow illustrate the stability of the compositions of the invention, as well as their therapeutic utility, with reference to Figures 1 and 2 appended. EXAMPLE 1
Divers mélanges de monoxyde d'azote et de gaz carbonique ont été préparés et conditionnés dans des bouteilles de type B5 en alliage léger, à base d'aluminium, commercialisées par S.M. GERZAT sous une pression de 24 bars. Dans ces mélanges, la concentration initiale du monoxyde d'azote a été fixée à 20 ppm. La stabilité de la concentration en NO a été étudiée pour trois bouteilles conservées à température ambiante sur une période de 16 mois.Various mixtures of nitrogen monoxide and carbon dioxide have been prepared and packaged in type B5 light alloy bottles, based on aluminum, sold by S.M. GERZAT under a pressure of 24 bars. In these mixtures, the initial concentration of nitric oxide was set at 20 ppm. The stability of the NO concentration was studied for three bottles kept at room temperature over a period of 16 months.
La valeur de la concentration en NO est mesurée par un analyseur à chimiluminescence danε la gamme de 0 à 100 ppm, calibré avant chaque mesure à l'aide d'un mélange étalon NO/N2 à 90 ppm. L'analyseur à chimiluminescence utilisé est le TOPAZE 2020 fabriqué par COSMA.The value of the NO concentration is measured by a chemiluminescence analyzer in the range from 0 to 100 ppm, calibrated before each measurement using a standard NO / N 2 mixture at 90 ppm. The chemiluminescence analyzer used is the TOPAZE 2020 manufactured by COSMA.
A l'issue d'une période de 16 mois, aucune décomposition du monoxyde d'azote dans les mélanges NO/C02 conservés à température ambiante n'a pu être détectée. De fait, les seules fluctuations mesurées dans la valeur de la concentration en NO restent inférieures à la précision de l'analyse.After a period of 16 months, no decomposition of nitrogen monoxide in the NO / C0 2 mixtures stored at room temperature could be detected. In fact, the only fluctuations measured in the value of the NO concentration remain less than the precision of the analysis.
Ces résultats confirment la stabilité des compositions médicamenteuses de l'invention.These results confirm the stability of the drug compositions of the invention.
EXEMPLE 2EXAMPLE 2
Cet exemple vise à démontrer l'efficacité de la composition NO/C02 de l'invention, administrée par insufflation intra-péritonéale, dans la lutte contre 1'hypoperfusion des organes abdominaux, et en particulier des reins.This example aims to demonstrate the effectiveness of the composition NO / C0 2 of the invention, administered by intraperitoneal insufflation, in the fight against hypoperfusion of the abdominal organs, and in particular of the kidneys.
8 porcs d'environ 25 à 30 kg ont été anesthésiés par injection intramusculaire de kétamine (20 mg/kg) et de mizadolam (0,1 mg/kg) . Après intubation, l'anesthésie est maintenue par injection de fentanyl (5 μg/kg/h) et de pancuronium (0,5 mg/kg/h) , et par inhalation d'un mélange de desflurane (5%), d'oxygène (50%) et de protoxyde d'azote (45%). On ajuste la ventilation mécanique pour maintenir une pression partielle télé-expiratoire de C02 inférieure à 40 mm Hg.8 pigs weighing approximately 25 to 30 kg were anesthetized by intramuscular injection of ketamine (20 mg / kg) and mizadolam (0.1 mg / kg). After intubation, anesthesia is maintained by injection of fentanyl (5 μg / kg / h) and pancuronium (0.5 mg / kg / h), and by inhalation of a mixture of desflurane (5%), oxygen (50%) and protoxide d 'nitrogen (45%). The mechanical ventilation is adjusted to maintain a partial expiratory pressure of C0 2 of less than 40 mm Hg.
Des capteurs de type Doppler© sont implantés sur l'artère rénale de manière à mesurer le diamètre du vaisseau artériel et la vitesse du sang afin d'évaluer le débit sanguin rénal moyen.Doppler © sensors are implanted on the renal artery so as to measure the diameter of the arterial vessel and the speed of the blood in order to assess the average renal blood flow.
D'autre part, une sonde urinaire est installée dans l'urètre afin de mesurer le débit urinaire.On the other hand, a urinary catheter is installed in the urethra in order to measure the urine flow.
Les 8 porcs sont divisés en 2 groupes de 4 porcs chacun. Ces 2 groupes de 4 porcs subissent une insufflation intra-péritonéale, pendant 2 heures et à une pression de 15 mm Hg, de:The 8 pigs are divided into 2 groups of 4 pigs each. These 2 groups of 4 pigs undergo intraperitoneal insufflation, for 2 hours and at a pressure of 15 mm Hg, of:
- C02 gazeux pour le groupe 1;- C0 2 gas for group 1;
- d'un mélange gazeux NO/C02 (dose de NO égale à 20 ppm) pour le groupe 2.- a NO / C0 2 gas mixture (NO dose equal to 20 ppm) for group 2.
On observe une chute du débit sanguin et de la diurèse dans les 2 groupes de porcs, dès le début de l'insufflation. Toutefois, la chute est moindre pour le groupe 2 (NO/C02 insufflé) . En effet, après insufflation, les valeurs de débit sanguin et de diurèse obtenues pour le groupe 2 sont supérieures de 20% à 30% à celles obtenues pour le groupe 1.A drop in blood flow and diuresis is observed in the 2 groups of pigs, from the start of insufflation. However, the drop is less for group 2 (NO / C0 2 blown). In fact, after insufflation, the blood flow and diuresis values obtained for group 2 are 20% to 30% higher than those obtained for group 1.
La composition gazeuse de N0/C02 de l'invention permet bel et bien de lutter contre les hypoperfusions des organes abdominaux, lorsqu'elle est administrée par voie intra-abdominale, c'est-à- dire extra ou intra-péritonéale, en permettant en particulier une augmentation du débit sanguin au niveau des organes abdominaux. The gaseous composition of N0 / C0 2 of the invention does indeed make it possible to combat hypoperfusions of the abdominal organs, when it is administered intra-abdominally, that is to say extra or intra-peritoneal, in allowing in particular an increase in blood flow to the abdominal organs.

Claims

REVENDICATIONS
1. Utilisation d'une composition gazeuse contenant du monoxyde d'azote (NO) et du dioxyde de carbone (C02) pour la fabrication dVun médicament gazeux destiné au traitement ou à la prophylaxie par voie intra-abdominale des hypoperfusions des organes abdominaux.1. Use of a gaseous composition containing nitrogen monoxide (NO) and carbon dioxide (C0 2 ) for the manufacture of a gaseous medicament intended for the treatment or prophylaxis by intra-abdominal route of hypoperfusions of the abdominal organs.
2. Utilisation selon la revendication 1, caractérisée en ce que ledit médicament gazeux comprend au moins un gaz choisi dans le groupe formé par le protoxyde d'azote, le xénon, le krypton et leurs mélanges.2. Use according to claim 1, characterized in that said gaseous medicament comprises at least one gas chosen from the group formed by nitrous oxide, xenon, krypton and their mixtures.
3. Utilisation selon l'une des revendications 1 ou 2, caractérisée en ce que ledit médicament gazeux contient une concentration efficace de NO.3. Use according to one of claims 1 or 2, characterized in that said gaseous medicament contains an effective concentration of NO.
4. Utilisation selon l'une des revendications 1 à 3, caractérisée en ce que ledit médicament gazeux contient une concentration de NO comprise entre 1 et 100 ppm.4. Use according to one of claims 1 to 3, characterized in that said gaseous medicament contains a concentration of NO of between 1 and 100 ppm.
5. Utilisation selon l'une des revendications 1 à 4, caractérisée en ce que ledit médicament gazeux contient une concentration de NO comprise entre 15 et 30 ppm. 5. Use according to one of claims 1 to 4, characterized in that said gaseous medicament contains a concentration of NO of between 15 and 30 ppm.
EP96934928A 1995-10-20 1996-10-17 Nitrogen monoxide composition for use as a drug Ceased EP0859620A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512345 1995-10-20
FR9512345 1995-10-20
PCT/FR1996/001624 WO1997015312A1 (en) 1995-10-20 1996-10-17 Nitrogen monoxide composition for use as a drug

Publications (1)

Publication Number Publication Date
EP0859620A1 true EP0859620A1 (en) 1998-08-26

Family

ID=9483741

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96934916A Expired - Lifetime EP0855912B1 (en) 1995-10-20 1996-10-15 Nitrogen monoxide composition for use as a drug
EP96934928A Ceased EP0859620A1 (en) 1995-10-20 1996-10-17 Nitrogen monoxide composition for use as a drug

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96934916A Expired - Lifetime EP0855912B1 (en) 1995-10-20 1996-10-15 Nitrogen monoxide composition for use as a drug

Country Status (9)

Country Link
US (2) US6051241A (en)
EP (2) EP0855912B1 (en)
JP (2) JPH11513703A (en)
AT (1) ATE209922T1 (en)
AU (2) AU701760B2 (en)
CA (1) CA2188238A1 (en)
DE (1) DE69617719D1 (en)
ES (1) ES2167608T3 (en)
WO (2) WO1997015311A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106497A (en) * 1997-01-31 2000-08-22 Medical Instrument Development Laboratories System and method for preventing an air embolism in a surgical procedure
EP0887076A3 (en) 1997-05-07 1999-03-31 Saturnus A.G. Adhesion prevention and an endoscopic insufflation system therefor
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
FR2775967B1 (en) * 1998-03-10 2000-06-23 Air Liquide SUPERCRITICAL CONDITIONED GAS MIXTURE CONTAINING CO2, NO AND POSSIBLY NEUTRAL GAS
DE19833014A1 (en) * 1998-07-23 2000-01-27 Messer Griesheim Gmbh Injectable anesthetic comprising noble gas(es) in gaseous form, also showing analgesic, sedative, antiinflammatory and muscle relaxant actions
US6503740B1 (en) 2000-02-22 2003-01-07 Biomin, Inc. Organically modified mineral materials containing engrafted bacteria for chemical contaminant decomposition
WO2001070289A2 (en) 2000-03-20 2001-09-27 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
US6676855B2 (en) * 2001-08-02 2004-01-13 Duke University Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
US20040225275A1 (en) * 2001-08-02 2004-11-11 Reynolds James Dixon Fetal physiology during maternal surgery or diagnosis
CN1668315A (en) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 Anti-spasmodic comprising xenon
JP2005533787A (en) * 2002-06-12 2005-11-10 メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Antispasmodic containing xenon
US20050255169A1 (en) * 2002-07-05 2005-11-17 Messer Griesheim Adjuvant containing xenon
DE10336768B4 (en) * 2002-08-10 2010-09-09 Air Liquide Deutschland Gmbh Drug for improving oxygenutilation
WO2004039415A2 (en) 2002-10-28 2004-05-13 Northgate Technologies Inc. Dual-capacity insufflator tube
US7654975B2 (en) * 2003-04-24 2010-02-02 Northgate Technologies, Inc. Mixed-gas insufflation system
CA2538456C (en) * 2003-10-07 2013-01-15 Northgate Technologies Inc. System and method for delivering a substance to a body cavity
CA2543680C (en) * 2003-10-31 2012-05-22 Trudell Medical International System and method for manipulating a catheter for delivering a substance to a body cavity
CN100475275C (en) * 2004-01-05 2009-04-08 董永华 Thromboembolism agent, storage and releasing device thereof
SE0402221D0 (en) 2004-09-14 2004-09-14 Aerocrine Ab Treatment of insufficient perfusion
WO2006089028A2 (en) * 2005-02-15 2006-08-24 Lab39, Llc Foaming compositions and methods
CA3099231A1 (en) * 2006-08-04 2008-02-07 Northgate Technologies Inc. In-dwelling port for access into a body
JP5581500B2 (en) * 2010-03-10 2014-09-03 学校法人北里研究所 Treatment agent and treatment apparatus for reducing ischemia / reperfusion injury
US11129911B2 (en) 2011-05-05 2021-09-28 Cedars-Sinai Medical Center Assessment of coronary heart disease with carbon dioxide
CA2845308C (en) 2011-05-05 2021-01-26 Cedars-Sinai Medical Center Assessment of coronary heart disease with carbon dioxide
CN110464709A (en) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 For treating the neuroprotective liposome composition and method of apoplexy
CA2905155C (en) 2013-03-15 2021-11-16 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
US9486600B2 (en) 2013-06-28 2016-11-08 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Nasal cannula assembly with inhalation valves communicating with a deformable reservoir
US9566407B2 (en) 2013-06-28 2017-02-14 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Nasal cannula assembly with flow control passage communicating with a deformable reservoir
US9492626B2 (en) 2013-06-28 2016-11-15 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Breathing assistance assemblies suitable for long term no therapy
US9522247B2 (en) 2013-06-28 2016-12-20 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Method of treating a patient having pulmonary hypertension by long term NO therapy
US9517318B2 (en) 2013-06-28 2016-12-13 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Method of delivering medical gases via a nasal cannula assembly with flow control passage communicating with a deformable reservoir
US9522248B2 (en) 2013-06-28 2016-12-20 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Breathing assistance apparatus for delivery of nitric oxide to a patient by means of a nasal cannula assembly with flow control passage
US10471094B2 (en) 2013-08-05 2019-11-12 Cedars-Sinai Medical Center Methods for reducing ischemia-reperfusion injury via targeted control of blood gases
US9572595B1 (en) 2014-03-05 2017-02-21 Northgate Technologies Inc. In-dwelling port for access into a body
GB2579240B (en) 2018-11-27 2020-12-16 Attgeno Ab New processes, compositions and medical uses
GB202007929D0 (en) 2020-05-27 2020-07-08 Attgeno Ab New medical uses
CN111840583B (en) * 2020-08-06 2023-03-28 温州医科大学 Pharmaceutical preparation for treating vascular endothelial injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
ES2082732T3 (en) * 1990-12-05 1997-12-16 Gen Hospital Corp TREATMENT OF REVERSIBLE PULMONARY VASOCONSTRICTION AND BRONCHO-CONSTRICTION.
US5536241A (en) * 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9715312A1 *

Also Published As

Publication number Publication date
AU701760B2 (en) 1999-02-04
JPH11513703A (en) 1999-11-24
EP0855912B1 (en) 2001-12-05
AU7305896A (en) 1997-05-15
US6051241A (en) 2000-04-18
CA2188238A1 (en) 1997-04-21
ES2167608T3 (en) 2002-05-16
JPH11513705A (en) 1999-11-24
EP0855912A1 (en) 1998-08-05
US5670177A (en) 1997-09-23
DE69617719D1 (en) 2002-01-17
WO1997015311A1 (en) 1997-05-01
WO1997015312A1 (en) 1997-05-01
ATE209922T1 (en) 2001-12-15
AU7305196A (en) 1997-05-15

Similar Documents

Publication Publication Date Title
EP0859620A1 (en) Nitrogen monoxide composition for use as a drug
CA2341601C (en) Use of selenium for treating patients suffering from systemic inflammatory response syndrome (sirs), and composition for implementing said treatment
Sprague et al. Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits.
FI119912B (en) Use of gaseous nitric oxide in the manufacture of a medicament for the treatment of vascular restenosis
Porter et al. Antioxidant therapy in the prevention of organ dysfunction syndrome and infectious complications after trauma: early results of a prospective randomized study
US5728705A (en) Method of inducing vasorelaxation to treat pulmonary hypertension
Lange et al. Role of nitric oxide in shock: the large animal perspective
WO2007049262A1 (en) Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
AU4581799A (en) Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
Şener et al. Protective effects of taurine against nicotine-induced oxidative damage of rat urinary bladder and kidney
WO1999037149A1 (en) Methods of treating cytotoxic damage
Sim Nitric oxide and pulmonary hypertension
WO2002009731A1 (en) Use of co for treating inflammation of upper airways or bronchi
Seethapathy et al. Pathophysiology and management of hyperammonemia in organ transplant patients
van Meurs et al. Hemorrhagic shock-induced endothelial cell activation in a spontaneous breathing and a mechanical ventilation hemorrhagic shock model is induced by a proinflammatory response and not by hypoxia
CA2180506C (en) Inhalation of nitrogen monoxide for the prevention and the treatment of inflammatory reactions
CA2235122A1 (en) Nitrogen monoxide composition for use as a drug
Scheibe et al. Glutamine and alanyl-glutamine dipeptide reduce mesenteric plasma extravasation, leukocyte adhesion and tumor necrosis factor-alpha (TNF-alpha) release during experimental endotoxemia
Napoli et al. Nitric oxide and other novel therapies for pulmonary hypertension
US20080248012A1 (en) Erythrocyte Function Modifying Substance
US20070264248A1 (en) Preparation for preventing or treating disorders caused by toxic constituents contained in fiber combustion smoke
Hendriks et al. The effects of hypertension and diabetes mellitus on the vascular reactivity of resistance arteries
EP1225913B1 (en) Use of nitric oxide for the treatment of airway constriction
Beghetti et al. Inhaled nitric oxide and congenital cardiac disease
Yorgancı et al. Detrimental effects of nitric oxide on mesenteric circulation during endotoxaemia and its reversal by aminoguanidine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/00 A, 7A 61P 43/00 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: L'AIR LIQUIDE, S.A. A DIRECTOIRE ET CONSEIL DE SUR

18R Application refused

Effective date: 20011220